Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 7, 2011

View Archived Issues

Phase I study assesses AstraZeneca chemokine CXCR2 receptor antagonist in healthy volunteers

Millennium Pharmaceuticals discloses updated results from ongoing phase I trial of MLN-9708

Novel chitosan-based antibacterial agent developed at Synedgen

Lundbeck synthesizes multiple metabotropic glutamate receptor modulators

BTG provides 6-month update

New biomarker panel predicts risk of adverse events in patients with chronic heart failure

Bavarian Nordic gains rights to NCI anticancer vaccine candidate

Shionogi presents new oxazolidinones with potent antibacterial activity in vitro and in vivo

Pharmalucia discloses new photosensitizing agents

Novel prostanoid DP1 receptor antagonist patented by Sanofi

X-BODY BioSciences partners with Tanabe Research Laboratories for antibody therapeutics

Lightlake announces plans for phase II trials of bulimia nervosa therapy

New PLK1 inhibitors developed

Pfizer licenses neratinib to Puma Biotechnology

Alexza Pharmaceuticals partners with Grupo Ferrer for Adasuve

New cross-linked multimeric proteins for Fabry's disease claimed by Protalix Biotherapeutics

Servier exercises option to acquire sole rights to high-impact Ampakine product

Biovest presents regulatory strategy for BiovaxID in follicular lymphoma

Theratechnologies discovers novel GRF peptide

Probiodrug reports novel glutaminyl-peptide cyclotransferase inhibitors

Enrollment complete in Peregrine phase II NSCLC trial

BioCancell recruits first patients in BC-819 pancreatic cancer study

Dynavax reports more data from phase III Heplisav study

Millennium withdraws sNDA for Velcade

FDA approves Lilly's Cialis for new indications

Metabolic Solutions Development receives NIH grant for MSDC-0602 program

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 2, 2026.
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...